Replimune Group (NASDAQ:REPL) posted its quarterly earnings data on Thursday. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.10), Fidelity Earnings reports.

Shares of NASDAQ REPL traded down $0.14 during trading hours on Friday, hitting $16.85. 67,591 shares of the stock were exchanged, compared to its average volume of 117,261. The company has a quick ratio of 9.85, a current ratio of 9.85 and a debt-to-equity ratio of 0.16. The company has a market cap of $548.31 million, a PE ratio of -16.20 and a beta of 2.99. The firm has a fifty day moving average price of $16.83 and a 200-day moving average price of $14.17. Replimune Group has a 12 month low of $10.00 and a 12 month high of $19.66.

In related news, Director Jason P. Rhodes purchased 1,100,000 shares of the business’s stock in a transaction on Monday, November 18th. The shares were acquired at an average price of $13.61 per share, for a total transaction of $14,971,000.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, major shareholder Fund Iv L.P. Omega purchased 220,000 shares of the business’s stock in a transaction on Monday, November 18th. The shares were bought at an average price of $13.61 per share, for a total transaction of $2,994,200.00. The disclosure for this purchase can be found here. Corporate insiders own 63.18% of the company’s stock.

REPL has been the subject of several recent analyst reports. Zacks Investment Research upgraded shares of Replimune Group from a “hold” rating to a “buy” rating and set a $20.00 price objective for the company in a research note on Friday, January 24th. HC Wainwright reiterated a “buy” rating and set a $24.00 price objective (down previously from $26.00) on shares of Replimune Group in a research note on Tuesday, January 21st. Chardan Capital reiterated a “buy” rating and set a $28.00 price objective on shares of Replimune Group in a research note on Thursday. ValuEngine upgraded shares of Replimune Group from a “sell” rating to a “hold” rating in a research note on Thursday, February 6th. Finally, Wedbush reduced their price objective on shares of Replimune Group from $30.00 to $12.50 and set an “outperform” rating for the company in a research note on Wednesday, November 20th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $23.42.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors.

Read More: What is a stock split?

Earnings History for Replimune Group (NASDAQ:REPL)

Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.